Compare CZFS & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZFS | VANI |
|---|---|---|
| Founded | 1984 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.6M | 81.2M |
| IPO Year | N/A | 2014 |
| Metric | CZFS | VANI |
|---|---|---|
| Price | $58.90 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 9.5K | ★ 185.4K |
| Earning Date | 01-29-2026 | 11-13-2025 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | ★ 24.64 | N/A |
| EPS | ★ 7.10 | N/A |
| Revenue | ★ $107,399,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.45 | N/A |
| P/E Ratio | $8.29 | ★ N/A |
| Revenue Growth | ★ 9.73 | N/A |
| 52 Week Low | $49.96 | $0.91 |
| 52 Week High | $66.96 | $1.92 |
| Indicator | CZFS | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 50.98 | 50.05 |
| Support Level | $60.78 | $1.35 |
| Resistance Level | $63.18 | $1.49 |
| Average True Range (ATR) | 1.79 | 0.08 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 49.34 | 36.36 |
Citizens Financial Services Inc is a Pennsylvania-chartered bank and trust company. The company through its banking subsidiary provides banking activities and services for individual, business, governmental and institutional customers. Its activities and services principally include checking, savings, and time deposit accounts; residential, commercial and agricultural real estate, commercial and industrial, state and political subdivision and consumer loans; and a variety of other specialized financial services. The Trust and Investment division of the Bank offers a full range of client investment, estate, mineral management, and retirement services.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.